<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>References </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>
<div class="uk-container">
    <p>AAP Committee on Infectious Diseases. Red Book, 2021.</p>
    <p>Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of
        antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362(8): 697-
        706.</p>
    <p>Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral
        therapy with
        tuberculosis treatment. N Engl J Med 2011; 365(16): 1492-501.</p>
    <p>Ahn C, Oh KH, Kim K, Lee KY, Lee JG, Oh MD, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid
        concentrations of isoniazid, pyrazinamide, and rifampin.
        Perit Dial Int 2003; 23(4): 362-7.</p>
    <p>American Thoracic Society and Centers for Disease Control and Prevention. Update: adverse event data and revised
        American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of
        latent tuberculosis infection--United States, 2003. MMWR Morb
        Mortal Wkly Rep 2003; 52(31): 735-9.</p>
    <p>American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and
        treatment of latent tuberculosis infection. Am J Respir Crit Care Med
        2000; 161(4 Pt 2): S221-47.
    </p>
    <p>Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of
        antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;
        365(16): 1471-81.</p>
    <p>Blumberg HM, Ernst JD. The Challenge of Latent TB Infection. JAMA 2016; 316(9): 931-3.</p>
    <p>Blumberg HM, Kempker RR. Interferon-gamma release assays for the evaluation of tuberculosis infection. JAMA 2014;
        312(14):
        1460-1.</p>
    <p>Blumberg HM, Watkins DL, Berschling JD, Antle A, Moore P, White N, et al. Preventing the nosocomial transmission
        of
        tuberculosis. Ann Intern Med 1995; 122(9): 658-63.</p>
    <p>Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of Recommendations for Use
        of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb
        Mortal
        Wkly Rep 2018; 67(25): 723-6.</p>
    <p>Centers for Disease Control and Prevention. Tuberculosis (TB) - Data and Statistics. Available at:
        https://www.cdc.gov/tb/
        statistics/default.htm. Last Update Date: October 25, 2021.</p>
    <p>Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus
        Statement of the Public Health Tuberculosis Guidelines
        Panel. JAMA 1998; 279(12): 943-8.</p>
    <p>Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment, Ahmad N, Ahuja SD,
        Akkerman OW, Alffenaar JC, Anderson LF, et al.
        Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient
        data meta-analysis. Lancet 2018; 392(10150): 821-34.</p>
    <p>Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents:
        Guidelines for the use of antiretroviral agents in HIV-1-
        infected adults and adolescents, 2021. </p> <div class="res-width" >https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.</div> 
    <p>Deutsch-Feldman M, Pratt RH, Price SF, Tsang CA, Self JL. Tuberculosis – 2020, United States. MMWR Morb Mortal Wkly Rep. 2021; 70(12):409-414. </p>
    <p>Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al and the AIDS Clinical Trials Group and Tuberculosis Trials Consortium. 
        Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705-1718.  </p>
    <p>Fargher J,
        Reuter A, Furin J. Demanding an end to tuberculosis: treatment of tuberculosis infection among persons living
        with and without HIV. Curr Opin
        HIV AIDS 2019; 14(1): 21-7.</p>
    <p>Furin J, Cox H, Pai M. Tuberculosis. Lancet 2020; 393(10181):1642-1656. </p>
    <p>Georgia
        Department of Public Health. 2016 Georgia Tuberculosis Report. 2021.</p>
    <p>Gupta A, Montepiedra G, Aaron L,
        Theron G, McCarthy K, Bradford S, et al. Isoniazid Preventive Therapy in HIV- Infected Pregnant and Postpartum
        Women. N Engl J Med 2019; 381(14): 1333-46.</p>
    <p>Hatzenbuehler
        LA, Starke JR. Treatment of tuberculosis infection in children. Expert Rev Anti Infect Ther 2018; 16(9):
        695-708.</p>
    <p>Havlir DV,
        Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1
        infection and tuberculosis. N Engl J Med 2011;
        365(16): 1482-91.</p>
    <p>Jensen PA,
        Lambert LA, Iademarco MF, Ridzon R, Cdc. Guidelines for preventing the transmission of Mycobacterium
        tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54(RR-17): 1-141.</p>
    <p>Kahwati LC,
        Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, et al. Primary Care Screening and Treatment for Latent
        Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task
        Force. JAMA 2016; 316(9): 970-83.</p>
    <p>Kunst H, Khan
        KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
        Int J Tuberc Lung Dis
        2010; 14(11): 1374-81.</p>
    <p>Lewinsohn DM, Leonard MK, LoBue
        PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/ Infectious Diseases Society of
        America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in
        Adults and Children. Clin Infect Dis 2017; 64(2): 111-5.</p>
    <p>Malone RS,
        Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide,
        and ethambutol. Am J Respir Crit Care Med 1999; 159(5 Pt 1): 1580-4.</p>
    <p>Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M. Infectious Diseases Learning Unit: Understanding Advances in the 
        Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Jul 17;8(8):ofab319. </p>
    <p>Meintjes G, Stek C, Blumenthal
        L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated
        IRIS. N Engl J Med 2018; 379(20): 1915-25.</p>
    <p>Menzies D,
        Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four Months of Rifampin or Nine Months of Isoniazid for
        Latent Tuberculosis in Adults. N Engl J Med 2018; 379(5): 440 -53.</p>
    <p>Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegia M, Jaramillo E, Zignol M, Kasaeva T. World Health 
        Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021 Jun 4;57(6):2003300. </p>
    <p>Nahid P, Dorman SE, Alipanah N,
        Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/ Centers for Disease Control and
        Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible
        Tuberculosis. Clin Infect Dis 2016; 63(7): e147-e95.</p>
    <p>Pai M,
        Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of
        <i>Mycobacterium tuberculosis </i>infection. Clin Microbiol Rev 2014; 27(1): 3-20.</p>
    <p>Sterling TR, Moro RN, Borisov
        AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and Other Systemic Drug Reactions Among Persons
        Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in
        the PREVENT Tuberculosis Study. Clin Infect Dis 2015; 61(4):
        527-35.</p>
    <p>Sterling TR,
        Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the
        National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69(No. RR-1): 1–11.DOI:</p><a class="res-width" href="http://dx.doi.org/10.15585/mmwr.rr6901a1">http://dx.doi.org/10.15585/mmwr.rr6901a1</a>
    <p>Sterling
        TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven- Sizemore E, et al. Three months of rifapentine and
        isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365(23): 2155-66.</p>
    <p>Tiberi S,
        du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, et al. Tuberculosis: progress and advances in development of
        new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018; 18(7):
        e183-e98.</p>
    <p>US Preventive Services Task
        Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW, et al. Screening for Latent Tuberculosis
        Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316(9): 962-9.</p>
    <p>World Health Organization. Latent
        tuberculosis infection. Updated and
        consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018. Available at:
        <a href="https://apps.who.int/iris/handle/10665/260233" class="res-width">https://apps.who.int/iris/handle/10665/260233</a> </p>
    <p>World Health Organization. Global
        tuberculosis report 2021. <a href="https://www.who.int/publications/i/item/9789240037021" class="res-width">https://www.who.int/publications/i/item/9789240037021</a></p>
    <p>World Health
        Organization. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment.
         Geneva: World Health Organization. Available at: <a href="https://www.who.int/publications/i/item/9789240007048" class="res-width">https://www.who.int/publications/i/item/9789240007048</a></p>
    <p>Zenner D,
        Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of Latent Tuberculosis Infection: An Updated
        Network Meta-analysis. Ann Intern Med 2017; 167(4):
        248-55.</p>
</div>
</body>

</html>
